Home/Pipeline/Oncology Vaccines

Oncology Vaccines

Cancer

Pre-clinicalActive

Key Facts

Indication

Cancer

Phase

Pre-clinical

Status

Active

Company

Glycan Therapeutics

About Glycan Therapeutics

Glycan Therapeutics is a private, pre-clinical stage biotech pioneering a new class of medicines based on glycobiology. The company's core technology platform enables the rational design of glycan-targeting molecules, including antibodies and vaccines, to modulate immune responses and disrupt disease mechanisms. Its initial pipeline focuses on oncology and infectious diseases, seeking to address limitations of current therapies. As a platform company, it operates a pre-revenue business model typical of early-stage biotechs, relying on venture funding and potential partnerships for advancement.

View full company profile

Therapeutic Areas

Oncology Infectious Disease

Other Cancer Drugs

Drug	Company	Phase	Status
Not Specified (Oncology Focus)	Narwhal Bio	Pre-clinical	Active
EDM Platform for Genetic Medicine	Coastar Therapeutics	Pre-clinical	Platform Development
CO-1	Caedo Oncology	Pre-clinical	Active R&D
Anti-CD99 monoclonal antibody	Caedo Oncology	Discovery/Pre-clinical	Proprietary antibody identified
Anti-HLA class I monoclonal antibody	Caedo Oncology	Discovery/Pre-clinical	Proprietary antibody identified
Triapine®	Nanopharmaceutics	Clinical	Active
Ammonium Tetrathiomolybdate	Nanopharmaceutics	Clinical	Active
Aza-TdC	Nanopharmaceutics	Clinical	Active
Undisclosed Oncology Program(s)	Cell BioEngines	Phase 1	Active
No-alpha IL-2 Mutein	SarcoMed USA	Pre-clinical	Active
PMIS Therapeutic	NaturemiRI	Preclinical/Clinical (unspecified)	Active
AUM302 (formerly IBL-302)	Inflection Biosciences	Pre-clinical (partnered)	Active